Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2251 - 2275 of 14939 in total
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of...
Approved
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that...
Approved
Investigational
Matched Description: … system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and ... currently indicated for the suppression of the immune system to prevent renal transplant rejection and ... Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic …
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults ... The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every ... The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Mifamurtide is an immunomodulator with antitumor activity via activation of macrophages and monocytes. Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP). MDP is a motif present in all gram-positive and...
Approved
Experimental
Matched Description: … receptors (NLRs) and toll-like receptors present in macrophages and monocytes. ... signalling molecules and activators such as nucleotide-binding and oligomerization domain (NOD)-like ... of bactericidal and tumoricidal effects [A31745]. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine . It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Approved
Matched Description: … Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions ... It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and
Matched Categories: … Alimentary Tract and Metabolism …
Boscalid has been investigated for the treatment of OSDI, Glaucoma, Staining, Schirmers, and Disease Severity, among others.
Approved
Experimental
Matched Description: … Boscalid has been investigated for the treatment of OSDI, Glaucoma, Staining, Schirmers, and Disease …
Thioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in foods from animal and plant products. It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site. It plays an essential role as an antioxidant in neutralizing food...
Approved
Matched Description: … foods from animal and plant products. ... Thioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in ... It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe pain, progressive multi-organ damage, and premature death. Treatment options for SCD are largely focused on preventing the production and circulation of...
Approved
Investigational
Matched Description: … [A262691] Treatment options for SCD are largely focused on preventing the production and circulation ... ] - a mainstay of treatment since the 1990s - as well as newer agents like [crizanlizumab] and [voxelotor ... [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease …
Matched Categories: … Blood and Blood Forming Organs …
Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. Hematopoietic stem cell transplantation (HSCT) is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Approved
Investigational
Matched Description: … A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.
Approved
Matched Description: … Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections. …
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … DM4 leads to cell-cycle arrest and apoptosis and is also able to diffuse into neighboring cells and induce ... [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and ... the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as...
Approved
Investigational
Matched Description: … It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment ... non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ... It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System …
Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Approved
The respiratory protein of the red blood cells. It consists primarily of globin and heme.
Approved
Experimental
Investigational
Matched Description: … It consists primarily of globin and heme. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
An imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key...
Approved
Investigational
Matched Description: … and maintenance of hemostasis [A18581]. ... in adult and pediatric patients with congenital FXIII deficiency [FDA Label]. ... in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Matched Description: … It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) ... [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Approved
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it...
Approved
Investigational
Vet approved
Matched Description: … It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic ... the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and
Matched Categories: … Alimentary Tract and Metabolism ... Belladonna and Derivatives, Plain ... butylscopolamine and analgesics …
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Matched Description: … the chronic complications such as chronic active hepatitis and cirrhosis. ... epidemiology vary widely among geographical areas and population subgroups. ... Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Bacterial and viral vaccines, combined ... haemophilus influenzae B and hepatitis B …
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. ... Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein ... Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization ... This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia ... Food and Drug Administration approved Crysvita (burosumab) in April 2018. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …
Displaying drugs 2251 - 2275 of 14939 in total